Get the Stockscreener App
1.37
0.00%
0.00
After Hours:
1.40
0.03
+2.19%
Scynexis Inc Stock (SCYX) Latest News
SCYNEXIS (NASDAQ:SCYX) adds US$6.5m to market cap in the past 7 days, though investors from five years ago are still down 86% - Simply Wall St
Avidity Partners Management LP's Strategic Acquisition in SCYNEX - GuruFocus.com
Federated Hermes, Inc. Increases Stake in SCYNEXIS Inc - GuruFocus.com
SCYX stock touches 52-week low at $1.25 amid market challenges By Investing.com - Investing.com South Africa
SCYX stock touches 52-week low at $1.25 amid market challenges - Investing.com
SCYNEXIS announces new $50 million equity sales agreement By Investing.com - Investing.com Australia
SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Scynexis Inc earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Scynexis: Q3 Earnings Snapshot - San Francisco Chronicle
SCYNEXIS announces new $50 million equity sales agreement - Investing.com India
SCYNEXIS Secures $10M GSK Milestone, Advances Antifungal Pipeline Despite Q3 Revenue Dip | SCYX Stock News - StockTitan
SCYNEXIS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. In - GuruFocus.com
Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years - Yahoo Finance
SCYNEXIS (NASDAQ:SCYX) Shares Pass Above Fifty Day Moving AverageShould You Sell? - MarketBeat
SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Below Two Hundred Day Moving AverageHere's Why - MarketBeat
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc - Yahoo Finance
SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200 Day Moving AverageTime to Sell? - MarketBeat
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 - The Manila Times
SCYNEXIS (NASDAQ:SCYX) Shares Pass Below 200 Day Moving Average of $1.82 - MarketBeat
CRISPR Therapeutics: Prepare To Be Bored (NASDAQ:CRSP) - Seeking Alpha
Potential Price Increase for Synopsys, Inc. (SNPS) After Recent Insider Activity - Knox Daily
Scynexis CEO acquires $27,400 in company stock By Investing.com - Investing.com Canada
Syncona Advances Share Buyback, Bolsters Treasury Shares - TipRanks
Xero buys South African firm for $115m in 'departure' - New Zealand Herald
SCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo Buys 20,000 Shares - MarketBeat
Scynexis CEO acquires $27,400 in company stock - Investing.com
Synectics says trading is 'significantly ahead' of previous guidance - Proactive Investors USA
Better than expected profits forecast for security tech company - The Business Desk
Synopsys Inc. stock rises Friday, still underperforms market - MarketWatch
SCYNEXIS (NASDAQ:SCYX) Stock Crosses Below 200-Day Moving Average of $1.83 - MarketBeat
SCYNEXIS Advances Antifungal Treatments, Strengthens Financial Outlook - TipRanks
SCYNEXIS (NASDAQ:SCYX) Shares Cross Below 200-Day Moving Average of $1.84 - MarketBeat
SCYX stock touches 52-week low at $1.35 amid market challenges - Investing.com
Financial Fitness Check: Examining Scynexis Inc (SCYX)’s Key Ratios - The Dwinnex
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
SCYNEXIS (NASDAQ:SCYX) Downgraded by StockNews.com to Sell - Defense World
SCYNEXIS (NASDAQ:SCYX) Downgraded to "Sell" at StockNews.com - MarketBeat
SCYNEXIS Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
SCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
Scynexis: Q2 Earnings Snapshot - San Antonio Express-News
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update - wallstreet:online
1.11%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):